Open AccessJournal Article
TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study.
TLDR
This small, open-label pilot study suggests that inhibition of the inflammatory cytokine TNF-alpha may hold promise as a potential approach to AD treatment and calls for further study in randomized, placebo-controlled clinical trials.Abstract:
Context: Current pharmacologic treatments for Alzheimer's disease (AD) do not prevent long-term clinical deterioration. Tumor necrosis factor (TNF)-alpha, a proinflammatory cytokine, has been implicated in the pathogenesis of AD. Objective: To investigate the use of a biologic TNF-alpha inhibitor, etanercept was given by perispinal extrathecal administration for the treatment of AD. Methods: This was a prospective, single-center, open-label, pilot (proof-of-concept) study, in which 15 patients with mild-to-severe AD were treated for 6 months. We administered etanercept, 25-50 mg, once weekly by perispinal administration. Main outcome measures included the Mini-Mental State Examination (MMSE), the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), and the Severe Impairment Battery (SIB). Results: The average age of our patient population was 76.7. The mean baseline MMSE was 18.2 (n = 15); the mean baseline ADAS-Cog was 20.8 (n = 11); and the mean baseline SIB was 62.5 (n = 5). There was significant improvement with treatment, as measured by all of the primary efficacy variables, through 6 months: MMSE increased by 2.13 ± 2.23, ADAS-Cog improved (decreased) by 5.48 ± 5.08, and SIB increased by 16.6 ± 14.52. Conclusion: An increasing amount of basic science and clinical evidence implicates inflammatory processes and resulting glial activation in the pathogenesis of AD. This small, open-label pilot study suggests that inhibition of the inflammatory cytokine TNF-alpha may hold promise as a potential approach to AD treatment. Further study in randomized, placebo-controlled clinical trials is merited.read more
Citations
More filters
Journal ArticleDOI
TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease
Melissa K. McCoy,Malú G. Tansey +1 more
TL;DR: If inactivation of TNF-dependent inflammation in the brain is warranted by additional pre-clinical studies, selective targeting of TNFR1-mediated signaling while sparing TNFR2 activation may lessen adverse effects of anti-TNF therapies in the CNS.
Journal ArticleDOI
Evidence for a cytokine model of cognitive function
TL;DR: The identified central role of cytokines in various brain activities during health provides greater insight into normal brain functions, especially synaptic plasticity, memory and cognition, and facilitates the understanding of specific biological mechanisms involved in neuropsychiatric diseases, such as dementia and depression.
Journal ArticleDOI
Interrelation of Oxidative Stress and Inflammation in Neurodegenerative Disease: Role of TNF
Roman Fischer,Olaf Maier +1 more
TL;DR: The dual role of TNF in promoting neurodegeneration and tissue regeneration via its two receptors is discussed, since stimulation via its second receptor, TNFR2, is neuroprotective and promotes tissue regeneration.
Journal ArticleDOI
Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.
Gabriel Olmos,Jerònia Lladó +1 more
TL;DR: This review summarizes the current knowledge of the cellular and molecular mechanisms by which TNF-α links the neuroinflammatory and excitotoxic processes that occur in several neurodegenerative diseases, but with a special emphasis on amyotrophic lateral sclerosis (ALS).
Journal ArticleDOI
Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder.
Márcia Kauer-Sant'Anna,Márcia Kauer-Sant'Anna,Flávio Kapczinski,Ana Cristina Andreazza,Ana Cristina Andreazza,David J. Bond,Raymond W. Lam,L. Trevor Young,Lakshmi N. Yatham +8 more
TL;DR: Examination of cytokine and BDNF levels in bipolar I disorder patients found that failure of inflammatory defences in the late stage of the disorder may account for reduction in BDNF and continued elevations in cytokines; thus these have the potential to serve as markers of illness progression in BD.
References
More filters
Journal ArticleDOI
Clinical diagnosis of Alzheimer's disease : report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
Guy M. McKhann,David A. Drachman,Marshall F. Folstein,Robert Katzman,Donald L. Price,Emanuel M. Stadlan +5 more
TL;DR: The criteria proposed are intended to serve as a guide for the diagnosis of probable, possible, and definite Alzheimer's disease; these criteria will be revised as more definitive information becomes available.
Journal ArticleDOI
Inflammation and Alzheimer's disease.
Haruhiko Akiyama,Steven W. Barger,Scott R. Barnum,B Bradt,Jürgen Bauer,Greg M. Cole,Neil R. Cooper,Piet Eikelenboom,Mark R. Emmerling,Bernd L. Fiebich,Caleb E. Finch,Sally A. Frautschy,W. S. T. Griffin,Harald Hampel,Michael Hüll,Gary E. Landreth,Lih-Fen Lue,Robert E. Mrak,Ian R. A. Mackenzie,Patrick L. McGeer,M K O'Banion,Joel S. Pachter,Giulio Maria Pasinetti,C Plata-Salaman,Joseph G. Rogers,Russell E. Rydel,Yueyang Shen,Wolfgang J. Streit,Ronald Strohmeyer,I Tooyoma,F L van Muiswinkel,R. Veerhuis,David G. Walker,Scott D. Webster,Beatrice Hauss–Wegrzyniak,Gary L. Wenk,Tony Wyss-Coray +36 more
TL;DR: By better understanding AD inflammatory and immunoregulatory processes, it should be possible to develop anti-inflammatory approaches that may not cure AD but will likely help slow the progression or delay the onset of this devastating disorder.
Journal ArticleDOI
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
Karen S. SantaCruz,Jada Lewis,Tara L. Spires,Jennifer B. Paulson,Linda Kotilinek,Martin Ingelsson,A. Guimaraes,Michael DeTure,Martin Ramsden,Eileen McGowan,Colleen L. Forster,Mei Yue,Jennifer D. Orne,Chris Janus,Ami Mariash,Michael A. Kuskowski,Bradley T. Hyman,Mike Hutton,Karen H. Ashe +18 more
TL;DR: NFTs are not sufficient to cause cognitive decline or neuronal death in this model of tauopathy, and after the suppression of transgenic tau, memory function recovered, and neuron numbers stabilized, but to the authors' surprise, NFTs continued to accumulate.
Journal ArticleDOI
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Ronald C. Petersen,Ronald G. Thomas,Michael Grundman,David A. Bennett,Rachelle S. Doody,Steven H. Ferris,Douglas Galasko,Shelia Jin,Jeffrey Kaye,Allan I. Levey,Eric Pfeiffer,Mary Sano,Christopher H. van Dyck,Leon J. Thal +13 more
TL;DR: Vitamin E had no benefit in patients with mild cognitive impairment and donepezil therapy was associated with a lower rate of progression to Alzheimer's disease during the first 12 months of treatment, a finding supported by the secondary outcome measures.
Journal ArticleDOI
The function of the vertebral veins and their rôle in the spread of metastases
TL;DR: In this paper, the authors examined the role of the vertebral veins in normal physiology and found that the distribution of these paradoxic metastases is not at all that of the nerve sheaths of the area as suggested by Warren et al.
Related Papers (5)
Inflammation and Alzheimer's disease.
Haruhiko Akiyama,Steven W. Barger,Scott R. Barnum,B Bradt,Jürgen Bauer,Greg M. Cole,Neil R. Cooper,Piet Eikelenboom,Mark R. Emmerling,Bernd L. Fiebich,Caleb E. Finch,Sally A. Frautschy,W. S. T. Griffin,Harald Hampel,Michael Hüll,Gary E. Landreth,Lih-Fen Lue,Robert E. Mrak,Ian R. A. Mackenzie,Patrick L. McGeer,M K O'Banion,Joel S. Pachter,Giulio Maria Pasinetti,C Plata-Salaman,Joseph G. Rogers,Russell E. Rydel,Yueyang Shen,Wolfgang J. Streit,Ronald Strohmeyer,I Tooyoma,F L van Muiswinkel,R. Veerhuis,David G. Walker,Scott D. Webster,Beatrice Hauss–Wegrzyniak,Gary L. Wenk,Tony Wyss-Coray +36 more